ReviewFrontiers in bioengineering and biotechnology2026
Industry-defined opportunities for advancing big data capabilities in biopharmaceutical manufacturing.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopharmaceuticals are the originating products of biotechnology, an area of increased focus for strategic U.S. leadership. The discovery, development, and manufacturing of biopharmaceuticals create large amounts of data, which is then managed and preserved for business and regulatory purposes. In accordance with the resource-based view management framework, this data is a resource which, when combined with the right capabilities, is foundational to building a company's competitive market advantage. Big Data Capabilities to acquire, analyze, curate, store, and use data for targeted purposes across the entire biopharmaceutical manufacturing lifecycle are key to realizing business value from big data collections. This paper describes these capabilities in relation to recent advances in biopharmaceutical manufacturing and the benefits these capabilities can help realize. We argue that developing shared capabilities benefits both individual businesses, who can adopt and adapt them to establish their own strategy and competitive advantage, as well as the entire industry, which advances biopharmaceutical science through shared knowledge and collaboration. This paper was derived from extensive material collected from biopharmaceutical manufacturing industry subject matter experts gathered by the Big Data Program of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.